The 9 analysts offering 12-month price forecasts for ATAI Life Sciences NV have a median target of 22.00, with a high estimate of 50.00 and a low estimate of 6.60. The median estimate represents a +379.83% increase from the last price of 4.59.
The current consensus among 10 polled investment analysts is to Buy stock in ATAI Life Sciences NV. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.23
Reporting Date Aug 15
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.